基于生物标志物的急性肾损伤管理：现实还是幻想？
Biomarker-Based Management of AKI: Fact or Fantasy?
机构信息
Department of Critical Care, King's College London, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Emergency Department, Guy's & St Thomas' Foundation Trust, London, UK.
出版信息
Nephron. 2022;146(3):295-301. doi: 10.1159/000518365. Epub 2021 Aug 26.
Abstract
New biomarkers for acute kidney injury (AKI) have improved our understanding of the etiology and pathogenesis of AKI. Depending on their origin, function, and kinetic profile, biomarkers have a role in screening, diagnosis, prognostication, and monitoring of AKI. This offers opportunities to improve the management of AKI, but concerns and limitations remain. In this review, we summarize the current role of new AKI biomarkers in the management of AKI and outline some of the ongoing limitations and challenges.
摘要
新的急性肾损伤 (AKI) 生物标志物提高了我们对 AKI 的病因和发病机制的认识。根据其来源、功能和动力学特征，生物标志物在 AKI 的筛查、诊断、预后和监测中具有一定作用。这为改善 AKI 的管理提供了机会，但仍存在一些关注和局限性。在这篇综述中，我们总结了新的 AKI 生物标志物在 AKI 管理中的作用，并概述了目前存在的一些局限性和挑战。
相似文献
1
Biomarker-Based Management of AKI: Fact or Fantasy?基于生物标志物的急性肾损伤管理：现实还是幻想？
Nephron. 2022;146(3):295-301. doi: 10.1159/000518365. Epub 2021 Aug 26.
2
Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement.急性疾病质量倡议共识会议关于急性肾损伤生物标志物的建议：共识声明。
JAMA Netw Open. 2020 Oct 1;3(10):e2019209. doi: 10.1001/jamanetworkopen.2020.19209.
3
Urinary neutrophil gelatinase-associated lipocalin: Acute kidney injury in liver cirrhosis.尿中性粒细胞明胶酶相关载脂蛋白：肝硬化中的急性肾损伤。
Clin Chim Acta. 2021 Dec;523:339-347. doi: 10.1016/j.cca.2021.10.015. Epub 2021 Oct 16.
4
Biomarker Predictors of Adverse Acute Kidney Injury Outcomes in Critically Ill Patients: The Dublin Acute Biomarker Group Evaluation Study.危重症患者不良急性肾损伤结局的生物标志物预测因素：都柏林急性生物标志物组评估研究。
Am J Nephrol. 2019;50(1):19-28. doi: 10.1159/000500231. Epub 2019 Jun 14.
5
Biomarker strategies to predict need for renal replacement therapy in acute kidney injury.预测急性肾损伤患者肾脏替代治疗需求的生物标志物策略。
Semin Dial. 2011 Mar-Apr;24(2):124-31. doi: 10.1111/j.1525-139X.2011.00830.x.
6
Recent developments in the detection and management of acute kidney injury.急性肾损伤检测与管理的最新进展
Arch Dis Child. 2017 Jan;102(1):91-96. doi: 10.1136/archdischild-2015-309381. Epub 2016 Aug 5.
7
Acute Kidney Injury: Biomarker-Guided Diagnosis and Management.急性肾损伤：生物标志物指导的诊断与管理。
Medicina (Kaunas). 2022 Feb 23;58(3):340. doi: 10.3390/medicina58030340.
8
Current concepts and advances in biomarkers of acute kidney injury.急性肾损伤生物标志物的当前概念和进展。
Crit Rev Clin Lab Sci. 2021 Aug;58(5):354-368. doi: 10.1080/10408363.2021.1879000. Epub 2021 Feb 8.
9
Biomarker-guided management of acute kidney injury.生物标志物指导下的急性肾损伤管理
Curr Opin Crit Care. 2020 Dec;26(6):556-562. doi: 10.1097/MCC.0000000000000777.
10
Tubular proteinuria in acute kidney injury: a critical evaluation of current status and future promise.急性肾损伤中的管状蛋白尿：对当前状况和未来前景的批判性评估。
Ann Clin Biochem. 2010 Jul;47(Pt 4):301-12. doi: 10.1258/acb.2010.010076. Epub 2010 May 28.
引用本文的文献
1
Absence of Kidney Tubular Injury in Patients With Acute Heart Failure With Acute Kidney Injury.急性肾损伤合并急性心力衰竭患者不存在肾小管损伤。
Circ Heart Fail. 2024 Nov;17(11):e011751. doi: 10.1161/CIRCHEARTFAILURE.123.011751. Epub 2024 Oct 18.
2
Biomarkers in acute kidney injury.急性肾损伤中的生物标志物
Ann Intensive Care. 2024 Sep 15;14(1):145. doi: 10.1186/s13613-024-01360-9.
3
Evaluating Progression Risk in Patients With Immunoglobulin A Nephropathy.评估免疫球蛋白A肾病患者的疾病进展风险
Kidney Int Rep. 2023 Sep 22;8(12):2515-2528. doi: 10.1016/j.ekir.2023.09.020. eCollection 2023 Dec.
4
Hypernatremia: Epidemiology and Predictive Role in Emerging and Established Acute Kidney Injury.高钠血症：在新发和已确诊急性肾损伤中的流行病学及预测作用
J Clin Med Res. 2023 Sep;15(8-9):399-405. doi: 10.14740/jocmr4990. Epub 2023 Sep 30.
5
Improvement of composite kidney outcomes by AKI care bundles: a systematic review and meta-analysis.AKI 护理包对改善复合肾脏结局的系统评价和荟萃分析。
Crit Care. 2023 Oct 9;27(1):390. doi: 10.1186/s13054-023-04641-0.
6
Indications for and Timing of Initiation of KRT.开始肾脏替代治疗的适应证和时机。
Clin J Am Soc Nephrol. 2023 Jan 1;18(1):113-120. doi: 10.2215/CJN.05450522. Epub 2022 Sep 13.
7
Acute Kidney Injury: Biomarker-Guided Diagnosis and Management.急性肾损伤：生物标志物指导的诊断与管理。
Medicina (Kaunas). 2022 Feb 23;58(3):340. doi: 10.3390/medicina58030340.
8
Cardiac Surgery Associated AKI Prevention Strategies and Medical Treatment for CSA-AKI.心脏手术相关急性肾损伤（CSA-AKI）的预防策略及药物治疗
J Clin Med. 2021 Nov 14;10(22):5285. doi: 10.3390/jcm10225285.
本文引用的文献
1
Prevention of Cardiac Surgery-Associated Acute Kidney Injury by Implementing the KDIGO Guidelines in High-Risk Patients Identified by Biomarkers: The PrevAKI-Multicenter Randomized Controlled Trial.通过对生物标志物识别的高危患者实施 KDIGO 指南预防心脏手术相关急性肾损伤：PrevAKI 多中心随机对照试验。
Anesth Analg. 2021 Aug 1;133(2):292-302. doi: 10.1213/ANE.0000000000005458.
2
Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement.急性疾病质量倡议共识会议关于急性肾损伤生物标志物的建议：共识声明。
JAMA Netw Open. 2020 Oct 1;3(10):e2019209. doi: 10.1001/jamanetworkopen.2020.19209.
3
Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study.持续急性肾损伤生物标志物的鉴定和验证：RUBY 研究。
Intensive Care Med. 2020 May;46(5):943-953. doi: 10.1007/s00134-019-05919-0. Epub 2020 Feb 6.
4
One-Year Prognosis of Kidney Injury at Discharge From the ICU: A Multicenter Observational Study.ICU 出院时肾脏损伤的 1 年预后：一项多中心观察性研究。
Crit Care Med. 2019 Dec;47(12):e953-e961. doi: 10.1097/CCM.0000000000004010.
5
Molecular nephrology: types of acute tubular injury.分子肾病学：急性肾小管损伤的类型。
Nat Rev Nephrol. 2019 Oct;15(10):599-612. doi: 10.1038/s41581-019-0184-x. Epub 2019 Aug 22.
6
Clinical use of [TIMP-2]•[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel.[TIMP-2]•[IGFBP7] 生物标志物检测在重症监护中评估急性肾损伤风险的临床应用：专家小组的指导意见。
Crit Care. 2019 Jun 20;23(1):225. doi: 10.1186/s13054-019-2504-8.
7
Association between urinary dickkopf-3, acute kidney injury, and subsequent loss of kidney function in patients undergoing cardiac surgery: an observational cohort study.心脏手术后尿 Dickkopf-3 与急性肾损伤及随后肾功能丧失的关系：一项观察性队列研究。
Lancet. 2019 Aug 10;394(10197):488-496. doi: 10.1016/S0140-6736(19)30769-X. Epub 2019 Jun 12.
8
Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Kidney in Sepsis and Septic Shock (Kid-SSS) Study.前脑啡肽原A 119 - 159（Penkid）是脓毒症急性肾损伤的早期生物标志物：脓毒症与脓毒性休克中的肾脏（Kid - SSS）研究。
Kidney Int Rep. 2018 Aug 22;3(6):1424-1433. doi: 10.1016/j.ekir.2018.08.006. eCollection 2018 Nov.
9
The Japanese Clinical Practice Guideline for acute kidney injury 2016.《2016年日本急性肾损伤临床实践指南》
J Intensive Care. 2018 Aug 13;6:48. doi: 10.1186/s40560-018-0308-6. eCollection 2018.
10
Biomarkers for prediction of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis.用于急性肾损伤肾替代治疗预测的生物标志物：系统评价和荟萃分析。
Intensive Care Med. 2018 Mar;44(3):323-336. doi: 10.1007/s00134-018-5126-8. Epub 2018 Mar 14.
Zotero 插件